Mark J. Ratain
Impact in
- Oncology top 0.1%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Drug Transport and Resistance Mechanisms
- Lung Cancer Research Studies
- Pharmacology top 0.02%
- Pharmacogenetics and Drug Metabolism
Papers in
- Oncology 193
- Cancer Treatment and Pharmacology 69
- Colorectal Cancer Treatments and Studies 44
-
- Cancer therapeutics and mechanisms 90
- Co-authors
- Federico Innocenti (66 shared papers)Jacqueline Ramı́rez (68 shared papers)Richard L. Schilsky (60 shared papers)Lalitha Iyer (15 shared papers)Walter M. Stadler (44 shared papers)Linda Janisch (57 shared papers)Lillian L. Siu (5 shared papers)Aaron R. Hansen (1 shared paper)
- Journals
- Journal of Clinical Oncology (134 papers)Clinical Pharmacology & Therapeutics (40 papers)Clinical Cancer Research (35 papers)Cancer Chemotherapy and Pharmacology (29 papers)Pharmacogenetics and Genomics (16 papers)
- Partner nations
- United StatesJapanChina
In The Last Decade
Mark J. Ratain
523 papers receiving 22.7k citations
Mark J. Ratain's Hit Papers
Peers
Comparison fields: 5 of 168
- Oncology 8.0k
- Pharmacology 2.5k
- Cancer Research 2.4k
- Molecular Biology 7.8k
- Pulmonary and Respiratory Medicine 3.4k
Countries citing papers authored by Mark J. Ratain
This map shows the geographic impact of Mark J. Ratain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Ratain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Ratain more than expected).
Fields of papers citing papers by Mark J. Ratain
This network shows the impact of papers produced by Mark J. Ratain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Ratain. The network helps show where Mark J. Ratain may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark J. Ratain, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 533 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tumour heterogeneity in the clinic Hit paper breakdown → | 2013 | 906 |
| 2 | Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2006 | 794 |
| 3 | Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan Hit paper breakdown → | 2004 | 697 |
| 4 | Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST) Hit paper breakdown → | 2016 | 621 |
| 5 | Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. Hit paper breakdown → | 1998 | 542 |
| 6 | UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity Hit paper breakdown → | 2002 | 524 |
| 7 | 2006 | 485 | |
| 8 | The development of a financial toxicity patient‐reported outcome in cancer: The COST measure Hit paper breakdown → | 2014 | 460 |
| 9 | Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer Hit paper breakdown → | 2011 | 449 |
| 10 | Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors Hit paper breakdown → | 2018 | 445 |
| 11 | 1995 | 399 | |
| 12 | 1999 | 279 | |
| 13 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy Hit paper breakdown → | 2018 | 240 |
| 14 | 1998 | 240 | |
| 15 | 2009 | 201 | |
| 16 | 2007 | 188 | |
| 17 | 2008 | 188 | |
| 18 | 2005 | 187 | |
| 19 | 2008 | 186 | |
| 20 | 1986 | 177 |
About Mark J. Ratain
Mark J. Ratain is a scholar working on Oncology, Molecular Biology, Pharmacology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 533 papers that have together received 23.2k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (90 papers), Pharmacogenetics and Drug Metabolism (75 papers), Cancer Treatment and Pharmacology (69 papers), Colorectal Cancer Treatments and Studies (44 papers), Cancer Genomics and Diagnostics (40 papers), Lung Cancer Treatments and Mutations (32 papers), Statistical Methods in Clinical Trials (29 papers) and Chronic Lymphocytic Leukemia Research (29 papers). The work is most often cited by research in Oncology (8.0k citations), Pharmacology (2.5k citations), Cancer Research (2.4k citations), Molecular Biology (7.8k citations) and Pulmonary and Respiratory Medicine (3.4k citations). Mark J. Ratain has collaborated with scholars based in United States, Japan and China. Frequent co-authors include Federico Innocenti, Jacqueline Ramı́rez, Richard L. Schilsky, Lalitha Iyer, Walter M. Stadler, Linda Janisch, Lillian L. Siu, Aaron R. Hansen, Philippe L. Bédard and Soma Das. Their work appears in journals such as Journal of Clinical Oncology, Clinical Pharmacology & Therapeutics, Clinical Cancer Research, Cancer Chemotherapy and Pharmacology and Pharmacogenetics and Genomics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.